Stockscreener 앱 받기
2.34
4.46%
0.10
전일 마감가:
$2.24
열려 있는:
$2.24
하루 거래량:
1.89M
Relative Volume:
0.74
시가총액:
$256.87M
수익:
순이익/손실:
$-209.38M
주가수익비율:
-1.2468
EPS:
-1.8768
순현금흐름:
$-179.81M
1주 성능:
+5.88%
1개월 성능:
-28.44%
6개월 성능:
-36.07%
1년 성능:
-41.21%
1일 변동 폭
$0.00
$0.00
1주일 범위
$2.165
$2.395
52주 변동 폭
$2.165
$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
2.34 | 256.87M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
514.65 | 130.44B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
242.08 | 96.65B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
807.48 | 83.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
869.72 | 54.69B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
384.50 | 43.50B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-08 | 업그레이드 | Goldman | Sell → Neutral |
| 2026-09-16 | 업그레이드 | Needham | Hold → Buy |
| 2026-09-01 | 재개 | Chardan Capital Markets | Buy |
| 2025-11-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-08-20 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-30 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-05-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-28 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-28 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | 다운그레이드 | Needham | Buy → Hold |
| 2025-05-27 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-30 | 개시 | Wedbush | Outperform |
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Quince Therapeutics, Inc. (IRLA) 경영진 분석 - Simply Wall Street
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease - The Manila Times
Latham & Watkins Advises on Rocket Pharmaceuticals’ Growth Facility - Latham & Watkins LLP
Rocket secures up to USD 150 million: what it means for Rocket Pharmaceuticals stock - AD HOC NEWS
Rocket secures up to USD 150 million: what it means for Rocket Pharmaceuticals stock - AD HOC NEWS
Rocket Pharmaceuticals Secures $150M Senior Secured Term Loan with Hercules Capital, Issues Warrants - Kalkine Media
Rocket Pharmaceuticals secures $150M credit facility - Investing.com
Rocket Pharmaceuticals secures $150M credit facility with Hercules Capital - StreetInsider
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital - Business Wire
Have Insiders Sold Rocket Pharmaceuticals Shares Recently? - simplywall.st
Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares By Investing.com - Investing.com UK
Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares By Investing.com - Investing.com Canada
Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals (RCKT) counsel sells shares to cover RSU tax bill - Stock Titan
Former Rocket Pharmaceuticals (RCKT) executive plans stock sale tied to equity award taxes - Stock Titan
RCKT 8-K FilingsRocket Pharmaceuticals, Inc. SEC 8-K - Stock Titan
Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares - Investing.com
Three patients count toward Rocket’s 12-patient gene therapy trial - stocktitan.net
Former Rocket Pharmaceuticals (RCKT) officer plans to sell 6,857 shares under an SEC trading rule - Stock Titan
Rocket Pharma (RCKT) executive plans sale of 75K shares tied to vested stock taxes - Stock Titan
Former Rocket Pharma (NASDAQ: RCKT) exec plans stock sale - Stock Titan
Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus By Investing.com - Investing.com Canada
Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus By Investing.com - Investing.com India
Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus - Investing.com
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
RCKT News | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals Inc. (RCKT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Rocket Pharma (NASDAQ: RCKT) to pull 2026 warrant listing - Stock Titan
RCKT Maintained by Chardan Capital -- Price Target Stays at $11. - GuruFocus
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Nigeria
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating - Investing.com
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Canada
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com India
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com UK
Rocket Pharmaceuticals (RCKT) Jumps 6.6% to $3.86 as Buyers Defend Key Support LevelGap Up Stocks - vinanet.vn
New Jersey's Rocket Pharma Strikes New Pay Deal For Its GC - Law360
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - GuruFocus
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares - Investing.com
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares By Investing.com - Investing.com India
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com India
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com UK
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock - Investing.com
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock - investing.com
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rocket Pharmaceuticals Inc 주식 (RCKT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Militello John | Former Officer |
Sep 15 '26 |
Proposed Sale |
3.30 |
6,897 |
22,730 |
0 |
| Militello John | Former Officer |
Sep 14 '26 |
Proposed Sale |
3.32 |
6,857 |
22,731 |
0 |
| Wilson Martin | Officer |
Sep 11 '26 |
Proposed Sale |
3.40 |
75,364 |
256,486 |
0 |
| Militello John | Former Officer |
Sep 11 '26 |
Proposed Sale |
3.40 |
8,923 |
30,368 |
0 |
| Wilson Martin | Officer |
Aug 18 '26 |
Proposed Sale |
3.38 |
631 |
2,134 |
0 |
| Militello John | Former Officer |
Aug 18 '26 |
Proposed Sale |
3.38 |
1,252 |
4,234 |
0 |
| Wilson Martin | General Counsel |
Aug 18 '26 |
Sale |
3.38 |
631 |
2,133 |
673,853 |
| Shah Gaurav | CEO |
Aug 18 '26 |
Sale |
3.38 |
2,293 |
7,753 |
1,056,594 |
| Shah Gaurav | Officer |
Aug 18 '26 |
Proposed Sale |
3.38 |
2,293 |
7,754 |
0 |
| Shah Gaurav | Officer |
Aug 13 '26 |
Proposed Sale |
3.38 |
2,837 |
9,592 |
0 |
1.08%
2.09%
자본화:
|
볼륨(24시간):